Authors: Hirte, H Goel, R Major, P Seymour, L Huan, S Stewart, D Yau, J Arnold, A Holohan, S Waterfield, B Bates, S Bennett, K Walsh, W Elias, I

Citation: H. Hirte et al., A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours, ANN ONCOL, 11(12), 2000, pp. 1579-1584

Authors: Miller, WH Reyno, LM Loewen, GR Huan, S Winquist, E Moore, M Cato, A Jaunakais, D Truglia, JA Matthews, S Dancey, J Eisenhauer, E

Citation: Wh. Miller et al., A phase I-II study of 9-cis retinoic acid and interferon-alpha 2b in patients with advanced renal-cell carcinoma: An NCIC Clinical Trials Group study, ANN ONCOL, 11(11), 2000, pp. 1387-1389

Authors: Stewart, DJ Goel, R Gertler, SZ Huan, S Tomiak, EM Yau, J Cripps, C Evans, WK

Citation: Dj. Stewart et al., Concurrent use of multiple low dose chemotherapy agents with differing mechanisms of action as a strategy vs passive resistance: A pilot study, INT J ONCOL, 15(4), 1999, pp. 693-699

Authors: Moore, MJ Winquist, EW Murray, N Tannock, IF Huan, S Bennett, K Walsh, W Seymour, L

Citation: Mj. Moore et al., Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada clinical trials group, J CL ONCOL, 17(9), 1999, pp. 2876-2881

Authors: Crook, JM Szumacher, E Malone, S Huan, S Segal, R

Citation: Jm. Crook et al., Intermittent androgen suppression in the management of prostate cancer, UROLOGY, 53(3), 1999, pp. 530-534